133 related articles for article (PubMed ID: 26554863)
1. Molecular determinants of chemotherapy resistance in ovarian cancer.
Cooley M; Fang P; Fang F; Nephew KP; Chien J
Pharmacogenomics; 2015 Nov; 16(16):1763-7. PubMed ID: 26554863
[No Abstract] [Full Text] [Related]
2. miRNAs and ovarian cancer: a miRiad of mechanisms to induce cisplatin drug resistance.
Samuel P; Pink RC; Brooks SA; Carter DR
Expert Rev Anticancer Ther; 2016; 16(1):57-70. PubMed ID: 26567444
[TBL] [Abstract][Full Text] [Related]
3. Why does chemotherapy stop affecting the cells of ovarian and breast tumors?
Kalinina EV; Chernov NN
Future Oncol; 2018 May; 14(12):1137-1140. PubMed ID: 29629566
[No Abstract] [Full Text] [Related]
4. Establishment of cisplatin-resistant ovarian yolk sac tumor cells and investigation of the mechanism of cisplatin resistance using this cell line.
Shibata K; Umezu T; Sakurai M; Kajiyama H; Yamamoto E; Ino K; Nawa A; Kikkawa F
Gynecol Obstet Invest; 2011; 71(2):104-11. PubMed ID: 21150160
[TBL] [Abstract][Full Text] [Related]
5. Gains of 1q21-q22 and 13q12-q14 are potential indicators for resistance to cisplatin-based chemotherapy in ovarian cancer patients.
Kudoh K; Takano M; Koshikawa T; Hirai M; Yoshida S; Mano Y; Yamamoto K; Ishii K; Kita T; Kikuchi Y; Nagata I; Miwa M; Uchida K
Clin Cancer Res; 1999 Sep; 5(9):2526-31. PubMed ID: 10499629
[TBL] [Abstract][Full Text] [Related]
6. [The mechanism of cisplatin-resistance in ovarian cancer].
Kikuchi Y
Hum Cell; 2001 Jun; 14(2):115-33. PubMed ID: 11552292
[TBL] [Abstract][Full Text] [Related]
7. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
Ji T; Gong D; Han Z; Wei X; Yan Y; Ye F; Ding W; Wang J; Xia X; Li F; Hu W; Lu Y; Wang S; Zhou J; Ma D; Gao Q
Cancer Lett; 2013 Dec; 341(2):231-9. PubMed ID: 23962558
[TBL] [Abstract][Full Text] [Related]
8. Low molecular weight heparin tinzaparin antagonizes cisplatin resistance of ovarian cancer cells.
Pfankuchen DB; Stölting DP; Schlesinger M; Royer HD; Bendas G
Biochem Pharmacol; 2015 Sep; 97(2):147-57. PubMed ID: 26239805
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy resistance in ovarian cancer: new molecular perspectives.
Coukos G; Rubin SC
Obstet Gynecol; 1998 May; 91(5 Pt 1):783-92. PubMed ID: 9572231
[TBL] [Abstract][Full Text] [Related]
10. Molecular mechanisms of platinum‑based chemotherapy resistance in ovarian cancer (Review).
Yang L; Xie HJ; Li YY; Wang X; Liu XX; Mai J
Oncol Rep; 2022 Apr; 47(4):. PubMed ID: 35211759
[TBL] [Abstract][Full Text] [Related]
11. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
12. Molecular profiling of platinum resistant ovarian cancer: use of the model in clinical practice.
Gevaert O; Pochet N; De Smet F; Van Gorp T; De Moor B; Timmerman D; Amant F; Vergote I
Int J Cancer; 2006 Sep; 119(6):1511; author reply 1512. PubMed ID: 16619247
[No Abstract] [Full Text] [Related]
13. The alkaloid emetine sensitizes ovarian carcinoma cells to cisplatin through downregulation of bcl-xL.
Sun Q; Yogosawa S; Iizumi Y; Sakai T; Sowa Y
Int J Oncol; 2015 Jan; 46(1):389-94. PubMed ID: 25310746
[TBL] [Abstract][Full Text] [Related]
14. Cancer: crossing over to drug resistance.
Livingston DM; Silver DP
Nature; 2008 Feb; 451(7182):1066-7. PubMed ID: 18305536
[No Abstract] [Full Text] [Related]
15. The passenger strand, miR-21-3p, plays a role in mediating cisplatin resistance in ovarian cancer cells.
Pink RC; Samuel P; Massa D; Caley DP; Brooks SA; Carter DR
Gynecol Oncol; 2015 Apr; 137(1):143-51. PubMed ID: 25579119
[TBL] [Abstract][Full Text] [Related]
16. [Expression of DNA transcription- and repair-related genes in cisplatin-resistant human ovarian carcinoma cell line COC1/DDP].
Cao MM; Zhang JR; Wang SM; Hu XG; Hu LJ
Di Yi Jun Yi Da Xue Xue Bao; 2005 Dec; 25(12):1478-81. PubMed ID: 16354609
[TBL] [Abstract][Full Text] [Related]
17. Ankyrin repeat domain 1, ANKRD1, a novel determinant of cisplatin sensitivity expressed in ovarian cancer.
Scurr LL; Guminski AD; Chiew YE; Balleine RL; Sharma R; Lei Y; Pryor K; Wain GV; Brand A; Byth K; Kennedy C; Rizos H; Harnett PR; deFazio A
Clin Cancer Res; 2008 Nov; 14(21):6924-32. PubMed ID: 18980987
[TBL] [Abstract][Full Text] [Related]
18. Role of the Nrf2-antioxidant system in cytotoxicity mediated by anticancer cisplatin: implication to cancer cell resistance.
Cho JM; Manandhar S; Lee HR; Park HM; Kwak MK
Cancer Lett; 2008 Feb; 260(1-2):96-108. PubMed ID: 18036733
[TBL] [Abstract][Full Text] [Related]
19. Ultrasound increases DNA damage attributable to cisplatin in cisplatin-resistant human ovarian cancer cells.
Yu T; Yang Y; Liu S; Yu H
Ultrasound Obstet Gynecol; 2009 Mar; 33(3):355-9. PubMed ID: 19204912
[TBL] [Abstract][Full Text] [Related]
20. "Recurrence within 6 months of platinum therapy": an adequate definition of "platinum-refractory" ovarian cancer?
Markman M
Gynecol Oncol; 1998 May; 69(2):91-2. PubMed ID: 9600812
[No Abstract] [Full Text] [Related]
[Next] [New Search]
